Valeant Pharmaceuticals (VRX) PT, Estimates Raised at Jefferies on Strong Q3
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Valeant Pharma (VRX) Reports Unsurprising Results Ahead of Dec. Meeting - FBR Capital
October 20, 2014 2:58 PM EDTFBR Capital affirms Valeant Pharma (NYSE: VRX) at Outperform with a price target of $148 following Q3 results reported today.
Analyst William Tanner noted the following key points from the quarter:3Q14 results what Valeant needed to show ahead of Special Meeting vote. Likely facing another attack from Allergan, we believe 3Q14 results may be more challenging to spin as evidence that the company's fundamentals are not strong and that the business model is flawed. One important general disclosure was that growth was driven more by volume than price, undercutting a potential argument... More
Valeant Pharma (VRX) Reports Q3 EPS of $2.11
October 20, 2014 7:03 AM EDTValeant Pharma (NYSE: VRX) reported Q3 EPS of $2.11, versus $1.43 reported last year. Revenue for the quarter came in at $2.06 billion, versus $1.54 billion reported last year.
Analysts were looking for EPS of $1.99.
Valeant sees FY14 cash EPS of $8.22 to $8.32 and Q4 EPS from $2.45... More
